ELZONRIS is the first and only approved treatment for BPDCN, a deadly hematologic cancer.2,3
The primary outcome of the study was the combined rate of CR and CRc among treatment-naive patients. All other data presented here were secondary outcomes.1,4
Efficacy in previously treated patients (initial analysis)1,2,4
Efficacy measures | Previously treated patients | (n=15)
---|---|
CR/CRc rate, % (n) | 13% (2) |
Median duration of CR/CRc, months Min, max |
Was not reached 3.7, 13.9 |
ORR, % (n) | 67% (10) |
Bridge to stem cell transplantation, % (n) |
7% (1) |
CRc, clinical complete response; defined as complete response with residual skin abnormality not indicative of active disease.2
BPDCN, blastic plasmacytoid dendritic cell neoplasm; CR, complete response; ORR, overall response rate.
Explore the baseline characteristics of previously treated patients in the study
Key baseline demographics in the study reflect the patient population and variable presentation of BPDCN.1,2,4
Baseline characteristics of previously treated patients (initial analysis)1,2,4
Characteristics | Previously treated patients | (n=15)
---|---|
Male, % (n) | 86.7% (13) |
Female, % (n) | 13.3% (2) |
Median age | (min, max)72 (44, 80) |
ECOG PS, % (n) | |
0 | 33.3% (5) |
1 | 66.7% (10) |
BPDCN, % (n) | |
Skin | 86.7% (13) |
Bone marrow | 60.0% (9) |
Peripheral blood | 6.7% (1) |
Lymph nodes | 53.3% (8) |
Visceral | 26.7% (4) |
Prior treatments, % (n) | |
Radiation therapy | 33.3% (5) |
Stem cell transplantation | 26.7% (4) |
ECOG PS, Eastern Cooperative Oncology Group performance status.
Previous lines of therapy (initial analysis)1,2
Number of lines | Previously treated patients (n=15) |
---|---|
1 | 60% (9) |
2-3 | 27% (4) |
≥4 | 13% (2) |
- References:
- Pemmaraju N, et al. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med. 2019;380(17):1628-1637.
- ELZONRIS [prescribing information]. New York, NY: Stemline Therapeutics, Inc.; November 2022.
- Pagano L, et al. Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches. Br J Haematol. 2016;174(2):188-202.
- Data on file. Stemline Therapeutics, Inc.